KR20140071277A - 면역조절 활성을 갖는 세포 집단, 그의 제조 방법 및 용도 - Google Patents

면역조절 활성을 갖는 세포 집단, 그의 제조 방법 및 용도 Download PDF

Info

Publication number
KR20140071277A
KR20140071277A KR1020137030844A KR20137030844A KR20140071277A KR 20140071277 A KR20140071277 A KR 20140071277A KR 1020137030844 A KR1020137030844 A KR 1020137030844A KR 20137030844 A KR20137030844 A KR 20137030844A KR 20140071277 A KR20140071277 A KR 20140071277A
Authority
KR
South Korea
Prior art keywords
cells
cell
population
protein
myelin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137030844A
Other languages
English (en)
Korean (ko)
Inventor
올가 드 라 로사
Original Assignee
타이제닉스, 에스.에이.유.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 타이제닉스, 에스.에이.유. filed Critical 타이제닉스, 에스.에이.유.
Publication of KR20140071277A publication Critical patent/KR20140071277A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1382—Adipose-derived stem cells [ADSC], adipose stromal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020137030844A 2011-05-19 2012-05-18 면역조절 활성을 갖는 세포 집단, 그의 제조 방법 및 용도 Ceased KR20140071277A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11166808.3 2011-05-19
EP11166808 2011-05-19
PCT/EP2012/059313 WO2012156522A1 (en) 2011-05-19 2012-05-18 Cell populations having immunoregulatory activity, methods for the preparation and uses thereof

Publications (1)

Publication Number Publication Date
KR20140071277A true KR20140071277A (ko) 2014-06-11

Family

ID=46149436

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137030844A Ceased KR20140071277A (ko) 2011-05-19 2012-05-18 면역조절 활성을 갖는 세포 집단, 그의 제조 방법 및 용도

Country Status (6)

Country Link
US (1) US20140348808A1 (enExample)
EP (1) EP2710122B1 (enExample)
JP (2) JP2014515258A (enExample)
KR (1) KR20140071277A (enExample)
ES (1) ES2487465T1 (enExample)
WO (1) WO2012156522A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011056972A2 (en) 2009-11-04 2011-05-12 Case Western Reserve University Compositions and methods of treating a t cell mediated disorder
FR2976580B1 (fr) * 2011-06-14 2013-05-31 Coatex Sas Epaississants non ioniques associatifs contenant des alkyls cyclohexylols, formulations les contenant et leurs utilisations.
EP3551749B1 (en) 2016-12-07 2023-09-27 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells
JP2021531280A (ja) * 2018-03-27 2021-11-18 スミス セラピューティクス インコーポレイテッド 神経変性疾患を処置するためのＣＡＲ−Ｔｒｅｇベースの治療
CN109913415B (zh) * 2019-03-26 2020-05-22 广东先康达生物科技有限公司 Treg细胞的培养液及其培养方法与应用
JP2024532516A (ja) * 2021-09-03 2024-09-05 サンガモ セラピューティクス，インコーポレイテッド Ｍｏｇ結合タンパク質及びその使用
WO2024046355A1 (en) * 2022-09-02 2024-03-07 Medical And Pharmaceutical Industry Technology And Development Center Use of composition including mesenchymal stem cells for alleviating myelofibrosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147865A1 (en) * 2002-02-07 2003-08-07 Benoit Salomon Cell therapy using immunoregulatory T-cells
CA2552891A1 (en) * 2004-01-08 2005-08-04 Regents Of The University Of California Regulatory t cells suppress autoimmunity
ES2563955T3 (es) * 2005-08-02 2016-03-16 Centenary Institute Of Cancer Medicine & Cell Biology Método para identificar linfocitos T reguladores
JP5925408B2 (ja) 2005-09-23 2016-05-25 タイジェニックス、ソシエダッド、アノニマ、ウニペルソナルＴｉｇｅｎｉｘ Ｓ．Ａ．Ｕ． 免疫調節活性を有する細胞集団、単離方法および使用
EP2050814A1 (en) * 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
EP2446022A4 (en) * 2009-05-18 2013-06-26 Therakos Inc PROCESS FOR THE EX-VIVO EXPANSION OF REGULATORY T CELLS WITH IMPROVED SUPPRESSION FUNCTION FOR CLINICAL APPLICATION IN IMMUNE-MEDIATED DISEASES
GB0918615D0 (en) 2009-10-23 2009-12-09 Cellerix Sa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof

Also Published As

Publication number Publication date
EP2710122B1 (en) 2021-03-31
EP2710122A1 (en) 2014-03-26
JP6592551B2 (ja) 2019-10-16
JP2014515258A (ja) 2014-06-30
JP2018134086A (ja) 2018-08-30
ES2487465T1 (es) 2014-08-20
US20140348808A1 (en) 2014-11-27
WO2012156522A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
Badillo et al. Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response
JP6592551B2 (ja) 免疫調節活性を有する細胞集団、その調製方法、及び、その使用
Shi et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases
US8221741B2 (en) Methods for modulating inflammatory and/or immune responses
US9011840B2 (en) Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
WO2009114860A2 (en) Activated mesenchymal stem cells for the prevention and repair of inflammatory states
JP2013507945A (ja) 免疫調節活性を有する細胞集団、その製造方法及び使用
JP6283347B2 (ja) 成熟樹状細胞集団の製造方法
CA2742698C (en) Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
US9173908B2 (en) Methods for modulating immune responses
Pappalardo Analysis of Immunomodulatory Properties of Spheroids from Adipose-derived Stem Cells
CN110337491A (zh) 免疫耐受性浆细胞样树突状细胞及其制备方法
US20230117738A1 (en) Generation of autoimmune inhibitory t cells by fibroblast mediated education
Kapranov et al. Co-culturing of multipotent mesenchymal stromal cells with autological and allogenic lymphocytes
WO2021248158A1 (en) Fibroblasts as a regenerative cellular source for the treatment of blindness
Brown Maintenance and modification of mesenchymal stromal cell immunosuppressive phenotype
Pittenger et al. Immunological properties of mesenchymal stem cells isolated from bone marrow and umbilical cord
JP2008526891A (ja) 移植された神経幹細胞の免疫防御のための骨髄間質細胞
Donders Mesenchymal stem cells derived from umbilical cord tissue: a therapeutic option for multiple sclerosis?
KR20150102383A (ko) Ex vivo로 조작된 생 자가세포 제조를 위한 자가유래 면역세포 배양방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131120

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170515

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180619

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181224

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190625

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20181224

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20180619

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190625

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190208

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180803

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20170515

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20191010

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190923

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20190625

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190208

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20181224

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180803

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180619

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170515